These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
Feb 27, 2018
- Ongoing SRA737 clinical studies expanded to target aggregate enrollment of 200 patients across ten cancer indications – - Adding new SRA737 monotherapy cohort for CCNE1-driven ovarian cancer -...
Feb 27, 2018
- Janssen to supply PARP inhibitor niraparib for Sierra's Phase 1b/2 combination trial with Chk1 inhibitor SRA737 - VANCOUVER, Feb. 27, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a...
Feb 21, 2018Sierra to Report Preclinical Data Demonstrating SRA737 Synergy with PARPi at the AACR 2018 Annual Meeting
Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) therapeutics for the treatment of patients with...
Feb 6, 2018
- Sierra also to present at the BIO CEO & Investor Conference in New York on February 12th - VANCOUVER, Feb. 6, 2018 /CNW/ - Sierra Oncology, Inc. (Nasdaq: SRRA), a clinical stage drug development...
Jan 29, 2018
- "Leveraging Synthetic Lethality to Enhance Clinical Trials with SRA737, a Next-Generation Chk1 Inhibitor" scheduled for 2:15 pm ET on February 1, 2018 in Boston - VANCOUVER, Jan. 29, 2018 /CNW/...